News and Insights
Numerof Appoints Former Chief Commercial Officer Ronald Kierpa as Senior Advisor
July 15, 2026
Veteran pharmaceutical and biotechnology leader brings decades of global commercial and launch expertise to Numerof clients
Numerof & Associates, a healthcare strategy consulting firm advising organizations across the life sciences ecosystem, today announced that Ronald Kierpa, a highly respected global commercial leader in pharmaceuticals and biotechnology, has joined the firm as a Senior Consultant and Client Engagement Manager.
In this role, Kierpa will partner with Numerof’s team to advise pharmaceutical, biotech, and medical device clients on strategic growth initiatives, commercialization and launch strategy, operating and engagement models, and evidence generation as market complexity, pricing pressure, and stakeholder expectations continue to intensify.
“Ron’s depth of experience anticipating market inflection points and translating scientific innovation into successful commercial execution aligns seamlessly with Numerof’s mission,” said Dr. Rita Numerof, President and co-founder. “He brings a special combination of global commercial leadership, operational rigor, and strategic insight that will be invaluable to clients making high-stakes decisions.”
Kierpa brings more than 30 years of leadership experience across major U.S. and global commercial pharma organizations, including Merck, Boehringer Mannheim, and Faraday Pharmaceuticals. He has spearheaded multiple product launches in marketing, sales, operations and market access across category-defining therapies, including the launch of Merck’s first biosimilar, RENFLEXIS, and the re-launch of their largest total revenue pharmaceutical at the time, ZOCOR.
Most recently, Kierpa served as Chief of Corporate Development and Commercial at Faraday, where he led product development teams, coordinated business development, and built the commercial platform for Faraday’s potential lead clinical program.
“In today’s markets, launching and growing products has become increasingly challenging. While evolving science remains critical, relevant evidence-based clinical data, patient journey recognition, demonstrated health economic value and appropriate reimbursement are essential levers for market success. Addressing these factors is key to helping ensure that important medicines reach the patients who need them,” said Kierpa. “Numerof is uniquely positioned to help organizations align strategy, evidence, and execution, and I’m excited to bring my experience to help clients make confident decisions at critical moments.”
About Numerof & Associates
Numerof & Associates is a strategy consulting firm that develops customized, market-based solutions for the strategic and operational challenges of organizations in industries undergoing significant transition. Working globally across the healthcare industry with clients in pharmaceuticals, medical devices and diagnostics, payers, and healthcare delivery, Numerof brings a unique cross-disciplinary approach to a broad range of engagements designed to sharpen strategic focus, increase revenues, reduce costs and risk, and enhance customer value.
Visit nai-consulting.com and connect with us on LinkedIn and X (Twitter).
Media Contact:
Jamie Shearer
Senior Account Executive, Pinkston
571.405.1606
numerof@pinkston.co
